JP5733880B2 - 抗癌剤に不応な腫瘍の治療及び化学感作のためのｃｋ２阻害剤の使用 - Google Patents

抗癌剤に不応な腫瘍の治療及び化学感作のためのｃｋ２阻害剤の使用 Download PDF

Info

Publication number
JP5733880B2
JP5733880B2 JP2008556646A JP2008556646A JP5733880B2 JP 5733880 B2 JP5733880 B2 JP 5733880B2 JP 2008556646 A JP2008556646 A JP 2008556646A JP 2008556646 A JP2008556646 A JP 2008556646A JP 5733880 B2 JP5733880 B2 JP 5733880B2
Authority
JP
Japan
Prior art keywords
peptide
tumor
combination
drug
combination drug
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2008556646A
Other languages
English (en)
Japanese (ja)
Other versions
JP2009528306A (ja
Inventor
ロドリゲス、シルビオ、エルネスト ペレア
ロドリゲス、シルビオ、エルネスト ペレア
ネグリン、ヤッサー ペレラ
ネグリン、ヤッサー ペレラ
ウリョア、アリエリス ロドリゲス
ウリョア、アリエリス ロドリゲス
バルデス、ヘオバニス ギル
バルデス、ヘオバニス ギル
ゴメス、ヤッセル ラモス
ゴメス、ヤッセル ラモス
セーラ、リラ、ロサ カステヤノス
セーラ、リラ、ロサ カステヤノス
ヌニェス、ラザロ、ハイラム ベタンクール
ヌニェス、ラザロ、ハイラム ベタンクール
プエンテ、アニエル サンチェス
プエンテ、アニエル サンチェス
デ コシーオ ドルタ デュケ、ホルヘ フェルナンデス
デ コシーオ ドルタ デュケ、ホルヘ フェルナンデス
カストロ、ボリス、エルネスト アセベド
カストロ、ボリス、エルネスト アセベド
ロペス、ルイス、ハビエル ゴンザレス
ロペス、ルイス、ハビエル ゴンザレス
ペレス、ウラジーミル ベサダ
ペレス、ウラジーミル ベサダ
アロンソ、ダニエル、フェルナンド
ゴメス、ダニエル、エドゥアルド
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Centro de Ingenieria Genetica y Biotecnologia CIGB
Original Assignee
Centro de Ingenieria Genetica y Biotecnologia CIGB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40134932&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP5733880(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Centro de Ingenieria Genetica y Biotecnologia CIGB filed Critical Centro de Ingenieria Genetica y Biotecnologia CIGB
Publication of JP2009528306A publication Critical patent/JP2009528306A/ja
Application granted granted Critical
Publication of JP5733880B2 publication Critical patent/JP5733880B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/136—Amines having aromatic rings, e.g. ketamine, nortriptyline having the amino group directly attached to the aromatic ring, e.g. benzeneamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/282—Platinum compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/69—Boron compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Inorganic Chemistry (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2008556646A 2006-02-28 2007-02-28 抗癌剤に不応な腫瘍の治療及び化学感作のためのｃｋ２阻害剤の使用 Expired - Fee Related JP5733880B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CU2006-0049 2006-02-28
CU20060049A CU23511B6 (es) 2006-02-28 2006-02-28 Combinación farmacéutica para el tratamiento y/o quimiosensibilización de tumores refractarios a drogas anticancerígenas
PCT/CU2007/000010 WO2007098719A1 (es) 2006-02-28 2007-02-28 Combinación farmaceutica para el tratamiento y/o quimiosensibilización de tumores refractarios a drogas anticancerígenas

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2013146681A Division JP2013231065A (ja) 2006-02-28 2013-07-12 抗癌剤に不応な腫瘍の治療及び化学感作のためのｃｋ２阻害剤の使用

Publications (2)

Publication Number Publication Date
JP2009528306A JP2009528306A (ja) 2009-08-06
JP5733880B2 true JP5733880B2 (ja) 2015-06-10

Family

ID=40134932

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2008556646A Expired - Fee Related JP5733880B2 (ja) 2006-02-28 2007-02-28 抗癌剤に不応な腫瘍の治療及び化学感作のためのｃｋ２阻害剤の使用
JP2013146681A Withdrawn JP2013231065A (ja) 2006-02-28 2013-07-12 抗癌剤に不応な腫瘍の治療及び化学感作のためのｃｋ２阻害剤の使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2013146681A Withdrawn JP2013231065A (ja) 2006-02-28 2013-07-12 抗癌剤に不応な腫瘍の治療及び化学感作のためのｃｋ２阻害剤の使用

Country Status (22)

Country Link
US (3) US8871725B2 (cg-RX-API-DMAC10.html)
EP (1) EP1997506B8 (cg-RX-API-DMAC10.html)
JP (2) JP5733880B2 (cg-RX-API-DMAC10.html)
KR (1) KR101454866B1 (cg-RX-API-DMAC10.html)
CN (1) CN101432012B (cg-RX-API-DMAC10.html)
AR (1) AR059645A1 (cg-RX-API-DMAC10.html)
AU (1) AU2007219572B2 (cg-RX-API-DMAC10.html)
BR (1) BRPI0708307B1 (cg-RX-API-DMAC10.html)
CA (1) CA2642943C (cg-RX-API-DMAC10.html)
CL (1) CL2015001086A1 (cg-RX-API-DMAC10.html)
CU (1) CU23511B6 (cg-RX-API-DMAC10.html)
CY (1) CY1114686T1 (cg-RX-API-DMAC10.html)
DO (1) DOP2007000040A (cg-RX-API-DMAC10.html)
MX (1) MX2008011141A (cg-RX-API-DMAC10.html)
MY (1) MY150135A (cg-RX-API-DMAC10.html)
NO (1) NO341904B1 (cg-RX-API-DMAC10.html)
PE (1) PE20081191A1 (cg-RX-API-DMAC10.html)
PL (1) PL1997506T3 (cg-RX-API-DMAC10.html)
RU (1) RU2396974C2 (cg-RX-API-DMAC10.html)
UY (1) UY30175A1 (cg-RX-API-DMAC10.html)
WO (1) WO2007098719A1 (cg-RX-API-DMAC10.html)
ZA (1) ZA200807323B (cg-RX-API-DMAC10.html)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CU23511B6 (es) * 2006-02-28 2010-04-13 Biorec B V Combinación farmacéutica para el tratamiento y/o quimiosensibilización de tumores refractarios a drogas anticancerígenas
GB0803352D0 (en) 2008-02-22 2008-04-02 Ntnu Technology Transfer As Oligopeptidic compounds and uses thereof
US20100173013A1 (en) * 2009-01-08 2010-07-08 Denis Drygin Treatment of neoplastic disorders using combination therapies
EP3866804A4 (en) 2018-10-19 2022-08-03 Senhwa Biosciences, Inc. Combinations for immune-modulation in cancer treatment
CN109875998B (zh) * 2019-01-24 2021-09-03 武汉大学 酰胺类生物碱在制备肿瘤化疗药物增敏剂中的应用及抗肿瘤药物组合物
CN110448699B (zh) * 2019-06-12 2022-03-11 天津医科大学 包含功能性多肽修饰七甲川花菁素类染料的肿瘤细胞核靶向载药纳米粒子及制备方法
CU20200103A7 (es) * 2020-12-18 2022-07-08 Ct Ingenieria Genetica Biotecnologia Péptido sintético para la inducción de inmunidad antitumoral y antiviral
CN114712377B (zh) * 2022-04-26 2023-08-15 江苏师范大学 断血流皂苷a在制造药物中的用途

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69738815D1 (de) * 1996-10-15 2008-08-14 Searle Llc Verwendung von Cyclooxygenase-2 Inhibitoren zur Behandlung und Vorbeugung von Neoplasia
CU23225A1 (es) * 2001-12-20 2007-08-30 Ct Ingenieria Genetica Biotech PéPTIDOS PARA EL TRATAMIENTO DEL CáNCER ASOCIADO AL VIRUS PAPILOMA HUMANO (VPH) Y DE OTROS TUMORES EPITELIALES
JP2005533748A (ja) * 2002-03-08 2005-11-10 シグナル ファーマシューティカルズ，インコーポレイテッド 増殖性障害および癌を治療、予防、または管理するための併用療法
US20060014987A1 (en) * 2003-07-07 2006-01-19 Lan Huang Synthesis of beta-elemene, intermediates thereto, analogues and uses thereof
WO2005049030A1 (en) * 2003-11-14 2005-06-02 Pharma Mar, S.A. Combination therapy comprising the use of et-743 and paclitaxel for treating cancer
CA2546920A1 (en) * 2003-12-09 2005-06-23 Joel Moss Methods for suppressing an immune response or treating a proliferative disorder
TW200538149A (en) * 2004-05-20 2005-12-01 Telik Inc Sensitization to another anticancer therapy and/or amelioration of a side effect of another anticancer therapy by treatment with a GST-activated anticancer compound
CU23511B6 (es) * 2006-02-28 2010-04-13 Biorec B V Combinación farmacéutica para el tratamiento y/o quimiosensibilización de tumores refractarios a drogas anticancerígenas

Also Published As

Publication number Publication date
NO20084119L (no) 2008-11-25
DOP2007000040A (es) 2007-09-30
MX2008011141A (es) 2009-01-26
CA2642943A1 (en) 2007-09-07
US8871725B2 (en) 2014-10-28
HK1132451A1 (en) 2010-02-26
KR101454866B1 (ko) 2014-11-04
US9278118B2 (en) 2016-03-08
EP1997506A1 (en) 2008-12-03
EP1997506B8 (en) 2013-02-20
BRPI0708307A2 (pt) 2011-05-24
KR20090030251A (ko) 2009-03-24
EP1997506B1 (en) 2012-12-05
CA2642943C (en) 2013-07-23
US20150030700A1 (en) 2015-01-29
US20150111832A1 (en) 2015-04-23
CU23511B6 (es) 2010-04-13
UY30175A1 (es) 2008-01-31
ZA200807323B (en) 2009-05-27
JP2009528306A (ja) 2009-08-06
CN101432012B (zh) 2013-01-02
CL2015001086A1 (es) 2016-05-13
JP2013231065A (ja) 2013-11-14
US20090130228A1 (en) 2009-05-21
US9226946B2 (en) 2016-01-05
AR059645A1 (es) 2008-04-16
BRPI0708307B1 (pt) 2019-07-23
RU2008138534A (ru) 2010-04-10
AU2007219572B2 (en) 2012-07-05
RU2396974C2 (ru) 2010-08-20
BRPI0708307B8 (cg-RX-API-DMAC10.html) 2021-05-25
AU2007219572A1 (en) 2007-09-07
NO341904B1 (no) 2018-02-19
CN101432012A (zh) 2009-05-13
CY1114686T1 (el) 2016-10-05
PL1997506T3 (pl) 2013-04-30
PE20081191A1 (es) 2008-09-24
WO2007098719A1 (es) 2007-09-07
MY150135A (en) 2013-11-29

Similar Documents

Publication Publication Date Title
JP5733880B2 (ja) 抗癌剤に不応な腫瘍の治療及び化学感作のためのｃｋ２阻害剤の使用
ES2349349T3 (es) Asociacion sinergica de (-)-gosipol con docetaxel o paclitaxel para el tratamiento de cancer.
CN100591331C (zh) 联合化疗组合物
KR102271848B1 (ko) 암 치료용 약학적 배합물
US8993587B2 (en) Combination of syrosingopine and mitochondrial inhibitors for the treatment of cancer and immunosuppression
Chen et al. Tetrandrine triggers apoptosis and cell cycle arrest in human renal cell carcinoma cells
JP2006503852A (ja) 抗癌薬としてのカスパーゼインヒビター
CA2922542A1 (en) Arylquinoline and analog compounds and use thereof to treat cancer
Mizutani et al. Chemoimmunosensitization of the T24 human bladder cancer line to Fas-mediated cytotoxicity and apoptosis by cisplatin and 5-fluorouracil.
KR20140035974A (ko) 종양 질환 치료를 위한 약제 조성물
Cortes et al. Farnesyltransferase inhibitors: novel compounds in development for the treatment of myeloid malignancies
ES2398586T3 (es) Uso del inhibidor de CK2 para el tratamiento y la quimiosensibilización de tumores refractarios a fármacos anticancerosos
Hwangbo et al. Auranofin accelerates spermidine-induced apoptosis via reactive oxygen species generation and suppression of PI3K/Akt signaling pathway in hepatocellular carcinoma
Al Khafaji et al. Anticancer and Antioxidant Effects of Sitagliptin and Linagliptin against Lung Cancer Cell Lines (an In vitro Study).
CN111773390A (zh) 一种药物在制备治疗脑转移瘤及其相关疾病的药品中的应用
KR102142164B1 (ko) 퀴논 화합물 및 암의 치료를 위한 그것의 용도
Filiberti et al. Pegylation approach applied to erlotinib–carbonic anhydrase inhibitors hybrids towards anticancer agents
HK1132451B (en) Use of ck2 inhibitor for the treatment and chemosensibilization of refractory tumors to anticancer drugs
Pastrone et al. Effect of the cisplatin-procaine complex DPR in combination with several anticancer agents on murine P388 leukemic cells in vitro and in vivo
Suksamai Effect of 5-o-(n-boc-l-alanine)-renieramycin t in the suppression of lung cancer stem cells
KR20130089030A (ko) 메틸 피오포바이드를 유효성분으로 포함하는 항암제 내성 극복 의약 조성물
CN116348145A (zh) 替莫唑胺和突变型idh1酶抑制剂的组合药物
Ko et al. 125 POSTER The antineoplastic activities of a novel oral formulation of interleukin-2 (IL-2)
JP2005120083A (ja) 抗腫瘍剤

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20100223

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20120508

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20120807

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20120814

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20120906

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20120913

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20121009

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20121016

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20121101

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20130312

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20130516

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20130516

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130712

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20130725

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20130920

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20140616

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20140620

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150212

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20150414

R150 Certificate of patent or registration of utility model

Ref document number: 5733880

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees